Clinical significance of mucinous components in rectal cancer after preoperative chemoradiotherapy

Abstract

The clinical implications of mucinous components in rectal tumors, especially with regard to the efficacy of neoadjuvant chemoradiotherapy, remain unclear. One hundred and thirty rectal cancer patients who received curative resection after neoadjuvant chemoradiotherapy were retrospectively reviewed. Patients were classified into 3 groups according to the proportion of extracellular mucin: low (<5%), moderate (5-25%), and high (>25%). There were 82 (63.1%), 26 (20.0%), and 22 (16.9%) patients in the low, moderate, and high mucin groups, respectively. Patients with a high mucinous tumor component were significantly more likely to have an advanced tumor stage (p=0.010) and a shorter disease-free (p=0.002) and distant recurrence-free survivals (p<0.001), whereas the mucinous tumor component showed no correlation with local recurrence (p=0.101). A high mucinous component was also an independent predictive factor for a shorter disease-free survival (p=0.041, hazard ratio=2.56) and distant recurrence-free survival (p=0.001, hazard ratio=5.74) according to a multivariate analysis. Because the mucinous components showed little correlation with local recurrence, mucinous cancer should not be a determining factor for chemoradiotherapy. However, the frequent occurrence of metachronous distant metastasis among patients with a high mucin component makes this a possible indicator for more robust postoperative adjuvant treatment and close surveillance of recurrence.